Subscribe
iko-shutterstock-com
iko / Shutterstock.com
20 August 2015Americas

Omeros to sue Par over generic Omidria application

Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria (phenylephrine and ketorolac injection).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Omeros cries foul over Par’s eye drug ANDA
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Omeros cries foul over Par’s eye drug ANDA
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.

More on this story

Americas
Omeros cries foul over Par’s eye drug ANDA
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility